Should I buy or sell SI-BONE stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SI-BONE in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SIBN shares. View SIBN analyst ratings or view top-rated stocks .

What is SI-BONE's stock price target for 2024?

5 brokers have issued 12-month target prices for SI-BONE's stock. Their SIBN share price targets range from $24.00 to $33.00. On average, they predict the company's stock price to reach $27.17 in the next twelve months. This suggests a possible upside of 39.8% from the stock's current price. View analysts price targets for SIBN or view top-rated stocks among Wall Street analysts .

How have SIBN shares performed in 2023?

SI-BONE's stock was trading at $13.60 at the beginning of the year. Since then, SIBN shares have increased by 42.9% and is now trading at $19.43. View the best growth stocks for 2023 here .

When is SI-BONE's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024. View our SIBN earnings forecast .

How were SI-BONE's earnings last quarter?

SI-BONE, Inc. (NASDAQ:SIBN) released its earnings results on Monday, November, 6th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.08. The business earned $34.01 million during the quarter, compared to the consensus estimate of $32.23 million. SI-BONE had a negative trailing twelve-month return on equity of 32.05% and a negative net margin of 32.98%.

What is Jeffrey Dunn's approval rating as SI-BONE's CEO?

10 employees have rated SI-BONE Chief Executive Officer Jeffrey Dunn on Glassdoor.com . Jeffrey Dunn has an approval rating of 41% among the company's employees. This puts Jeffrey Dunn in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of SI-BONE own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SI-BONE investors own include CVS Health (CVS) , Home Depot (HD) , Procter & Gamble (PG) , RTX (RTX) , Thermo Fisher Scientific (TMO) , Verizon Communications (VZ) , Alibaba Group (BABA) , Cisco Systems (CSCO) and CSX (CSX) .

When did SI-BONE IPO?

(SIBN) raised $84 million in an initial public offering (IPO) on Wednesday, October 17th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

Who are SI-BONE's major shareholders?

SI-BONE's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Brown Advisory Inc. (10.32%), Morgan Stanley (2.00%), Allspring Global Investments Holdings LLC (1.75%), Wellington Management Group LLP (1.50%), Impax Asset Management Group plc (1.23%) and Paradigm Capital Management Inc. NY (0.96%). Insiders that own company stock include Anshul Maheshwari, Anthony J Recupero, Anthony J Recupero , Gregory K Hinckley , Jeffrey W Dunn, Jeffrey W Dunn , Jeryl L Hilleman, Jeryl L Hilleman , John Gordon Freund , Laura Francis , Michael A Pisetsky and Michael A Pisetsky . View institutional ownership trends .

How do I buy shares of SI-BONE?

Shares of SIBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Does SI-BONE have any subsidiaries?

The following companies are subsidiares of SI-BONE: SI-BONE Deutschland GmbH, SI-BONE S.R.L., and SI-BONE UK LTD. Read More

SI-BONE (SIBN) Stock Price, News & Analysis

$19.42

+0.08 (+0.41%)

(As of 04:24 PM ET)

Compare

Today's Range: $18.93
▼
$19.50
50-Day Range: $15.75
▼
$21.19
52-Week Range: $11.23
▼
$29.51

Volume: 375,376 shs
Average Volume: 354,740 shs
Market Capitalization: $786.51 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $27.17

SI-BONE MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 39.8% Upside
$27.17 Price Target
Short Interest: Healthy
2.30% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.44
Upright™ Environmental Score
News Sentiment: 0.33
Based on 3 Articles This Week
Insider Trading: Selling Shares
$761,439 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.14) to ($0.97) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

Medical Sector

396th out of 943 stocks

Surgical & Medical Instruments Industry

50th out of 92 stocks

3.5

Analyst's Opinion

Consensus Rating
SI-BONE has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $27.17, SI-BONE has a forecasted upside of 39.8% from its current price of $19.43.
Amount of Analyst Coverage
SI-BONE has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.30% of the outstanding shares of SI-BONE have been sold short.
Short Interest Ratio / Days to Cover
SI-BONE has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in SI-BONE has recently increased by 7.38%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
SI-BONE does not currently pay a dividend.
Dividend Growth
SI-BONE does not have a long track record of dividend growth.

3.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
SI-BONE has received a 34.81% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Cervical implants" product. See details.
Environmental Sustainability
The Environmental Impact score for SI-BONE is -1.44.

2.4

News and Social Media Coverage

News Sentiment
SI-BONE has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for SI-BONE this week, compared to 1 article on an average week.
MarketBeat Follows
2 people have added SI-BONE to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, SI-BONE insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $761,439.00 in company stock.
Percentage Held by Insiders
Only 5.40% of the stock of SI-BONE is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for SI-BONE are expected to grow in the coming year, from ($1.14) to ($0.97) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of SI-BONE is -16.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of SI-BONE is -16.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
SI-BONE has a P/B Ratio of 6.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About SI-BONE Stock (NASDAQ:SIBN)

SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and distributors. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

SIBN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SIBN Stock News Headlines

December 6, 2023 | americanbankingnews.com

SI-BONE (NASDAQ:SIBN) Stock Rating Reaffirmed by Needham & Company LLC

December 5, 2023 | markets.businessinsider.com

SI-Bone: Strong Fundamentals and Impending Profitability Underpin Buy Rating

December 11, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

December 4, 2023 | benzinga.com

SI-BONE Stock (NASDAQ:SIBN), Analyst Ratings, Price Targets, Predictions

November 30, 2023 | benzinga.com

SI-BONE Stock (NASDAQ:SIBN) Dividends: History, Yield and Dates

November 30, 2023 | finance.yahoo.com

Si-Bone (SIBN) Crossed Above the 50-Day Moving Average: What That Means for Investors

November 23, 2023 | morningstar.com

SI-BONE Inc SIBN

November 21, 2023 | finance.yahoo.com

Insider Sell: President, Commercial Ops Anthony Recupero Sells 8,457 Shares of SI-BONE Inc (SIBN)

December 11, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

November 16, 2023 | seekingalpha.com

Sizing Up SI-BONE After Q3 Earnings

November 14, 2023 | finance.yahoo.com

SI-BONE To Present at Piper Sandler 35th Annual Healthcare Conference on November 28, 2023

November 7, 2023 | markets.businessinsider.com

Cantor Fitzgerald Maintains Overweight Rating for SI-BONE: Here's What You Need To Know

November 7, 2023 | finance.yahoo.com

SI-BONE, Inc. (NASDAQ:SIBN) Q3 2023 Earnings Call Transcript

November 6, 2023 | msn.com

SI-BONE GAAP EPS of -$0.25 beats by $0.09, revenue of $34M beats by $1.62M

November 6, 2023 | finance.yahoo.com

SI-BONE, Inc. Reports Record Financial Results for the Third Quarter 2023 and Raises Annual Guidance

November 6, 2023 | finance.yahoo.com

SI-BONE, Inc. Reports Record Financial Results for the Third Quarter 2023 and Raises Annual Guidance

November 6, 2023 | finance.yahoo.com

SI-BONE Inc (SIBN) Reports Record Q3 2023 Financial Results, Raises Annual Guidance

November 5, 2023 | finance.yahoo.com

The past three years for SI-BONE (NASDAQ:SIBN) investors has not been profitable

November 5, 2023 | markets.businessinsider.com

SI-BONE earnings preview: what Wall Street is expecting

November 1, 2023 | finance.yahoo.com

SI-BONE To Present at Jefferies London Healthcare Conference on November 15, 2023

October 16, 2023 | finance.yahoo.com

SI-BONE to Report Third Quarter 2023 Financial Results on November 6, 2023

October 9, 2023 | finance.yahoo.com

Si-Bone (SIBN) Upgraded to Buy: Here's Why

September 8, 2023 | finance.yahoo.com

Has SiBone (SIBN) Outpaced Other Medical Stocks This Year?

September 6, 2023 | finance.yahoo.com

Does Si-Bone (SIBN) Have the Potential to Rally 39.93% as Wall Street Analysts Expect?

September 5, 2023 | finance.yahoo.com

SI-BONE, Inc. Announces iFuse Bedrock Granite® Implant System Compatibility with Certain Medtronic CD Horizon® Solera® 5.5/6.0 System Rods

August 31, 2023 | msn.com

SI-BONE: Another Record Quarter, Reinvesting For Future Growth, Reiterate Buy

August 29, 2023 | finance.yahoo.com

SI-BONE To Present at Morgan Stanley 21st Annual Global Healthcare Conference on September 12, 2023

See More Headlines

Receive SIBN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SI-BONE and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/06/2023
Today: 12/11/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/26/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SIBN
CUSIP: N/A
CIK: 1459839
Web: www.si-bone.com
Phone: (408) 207-0700
Fax: N/A
Employees: 357
Year Founded: 2008

Price Target and Rating

Average Stock Price Target: $27.17
High Stock Price Target: $33.00
Low Stock Price Target: $24.00
Potential Upside/Downside: +39.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.19)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-61,260,000.00
Net Margins: -32.98%
Pretax Margin: -32.98%
Return on Equity: -32.05%
Return on Assets: -22.57%

Debt

Debt-to-Equity Ratio: 0.21
Current Ratio: 10.89
Quick Ratio: 9.74

Sales & Book Value

Annual Sales: $106.41 million
Price / Sales: 7.40
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.85 per share
Price / Book: 6.82

Miscellaneous

Outstanding Shares: 40,500,000
Free Float: 38,314,000
Market Cap: $786.92 million
Optionable: Not Optionable
Beta: 1.01

Social Links

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Ms. Laura A. Francis MBA (Age 56)
CEO & Director
Comp: $1.11M
Mr. Anshul Maheshwari (Age 43)
Chief Financial Officer
Comp: $614.25k
Mr. Anthony J. Recupero (Age 64)
President of Commercial Operations
Comp: $795.32k
Mr. Jeff Bertolini
Senior Vice President of Operations & Information Technology
Dr. Scott A. Yerby (Age 55)
Senior VP of Engineering & CTO
Mr. Michael A. Pisetsky (Age 45)
Chief Business & Legal Affairs Officer
Ms. Aimee Einstein
Vice President of People & Culture
Dr. Daniel Joseph Cher (Age 58)
Senior Vice President of Clinical & Regulatory Affairs
Dr. W. Carlton Reckling (Age 61)
Chief Medical Officer & VP of Medical Affairs
Mr. Nikolas F. Kerr (Age 51)
Senior Vice President of Product, Strategy & Business Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SIBN Stock Analysis - Frequently Asked Questions

Should I buy or sell SI-BONE stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SI-BONE in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SIBN shares.
View SIBN analyst ratings or view top-rated stocks.
What is SI-BONE's stock price target for 2024?: 5 brokers have issued 12-month target prices for SI-BONE's stock. Their SIBN share price targets range from $24.00 to $33.00. On average, they predict the company's stock price to reach $27.17 in the next twelve months. This suggests a possible upside of 39.8% from the stock's current price.
View analysts price targets for SIBN or view top-rated stocks among Wall Street analysts.
How have SIBN shares performed in 2023?: SI-BONE's stock was trading at $13.60 at the beginning of the year. Since then, SIBN shares have increased by 42.9% and is now trading at $19.43.
View the best growth stocks for 2023 here.
When is SI-BONE's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our SIBN earnings forecast.
How were SI-BONE's earnings last quarter?: SI-BONE, Inc. (NASDAQ:SIBN) released its earnings results on Monday, November, 6th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.08. The business earned $34.01 million during the quarter, compared to the consensus estimate of $32.23 million. SI-BONE had a negative trailing twelve-month return on equity of 32.05% and a negative net margin of 32.98%.
What is Jeffrey Dunn's approval rating as SI-BONE's CEO?: 10 employees have rated SI-BONE Chief Executive Officer Jeffrey Dunn on Glassdoor.com. Jeffrey Dunn has an approval rating of 41% among the company's employees. This puts Jeffrey Dunn in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of SI-BONE own?: Based on aggregate information from My MarketBeat watchlists, some companies that other SI-BONE investors own include CVS Health (CVS), Home Depot (HD), Procter & Gamble (PG), RTX (RTX), Thermo Fisher Scientific (TMO), Verizon Communications (VZ), Alibaba Group (BABA), Cisco Systems (CSCO) and CSX (CSX).
When did SI-BONE IPO?: (SIBN) raised $84 million in an initial public offering (IPO) on Wednesday, October 17th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.
Who are SI-BONE's major shareholders?: SI-BONE's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Brown Advisory Inc. (10.32%), Morgan Stanley (2.00%), Allspring Global Investments Holdings LLC (1.75%), Wellington Management Group LLP (1.50%), Impax Asset Management Group plc (1.23%) and Paradigm Capital Management Inc. NY (0.96%). Insiders that own company stock include Anshul Maheshwari, Anthony J Recupero, Anthony J Recupero, Gregory K Hinckley, Jeffrey W Dunn, Jeffrey W Dunn, Jeryl L Hilleman, Jeryl L Hilleman, John Gordon Freund, Laura Francis, Michael A Pisetsky and Michael A Pisetsky.
View institutional ownership trends.
How do I buy shares of SI-BONE?: Shares of SIBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
Does SI-BONE have any subsidiaries?: The following companies are subsidiares of SI-BONE: SI-BONE Deutschland GmbH, SI-BONE S.R.L., and SI-BONE UK LTD.
Read More

This page (NASDAQ:SIBN) was last updated on 12/11/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

SI-BONE (SIBN) Stock Price, News & Analysis

SI-BONE MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About SI-BONE Stock (NASDAQ:SIBN)

SIBN Stock Price History

SIBN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

SIBN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™